These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 12171908)

  • 21. In vitro inducing effect of dendritic cells cotransfected with survivin and granulocyte-macrophage colony-stimulating factor on cytotoxic T cell to kill leukemic cells.
    Zhu XP; Chen ZZ; Li CT; Lin X; Zhuang JL; Hu JD; Yang T; Xu ZS
    Chin Med J (Engl); 2008 Nov; 121(21):2180-4. PubMed ID: 19080181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
    Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
    Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
    Tai KF; Chen PJ; Chen DS; Hwang LH
    J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W; Yang H; Wang Z; Jim X
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
    Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
    Loskog A; Tötterman TH; Böhle A; Brandau S
    Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
    Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin alpha recombinant adenoviral vectors against Lewis lung carcinoma.
    Xie J; Xiong L; Tao X; Li X; Su Y; Hou X; Shi H
    Lung Cancer; 2010 Jun; 68(3):338-45. PubMed ID: 19671483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
    Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
    Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
    Wang L; Qi X; Sun Y; Liang L; Ju D
    Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Construction of eukaryotic expression vector of mouse alpha-fetoprotein cDNA and its expression in dendritic cells and in vitro antitumor effect on hepatoma].
    Zeng B; Lu FG; Liu XW; Yang DY; Fang WY; Wang J; Liao AJ; Shi W
    Ai Zheng; 2005 Nov; 24(11):1332-7. PubMed ID: 16552958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
    Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
    Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.